Serotonin syndrome (SS) and neuroleptic malignant syndrome (NMS) are uncommon but potentially life-threatening adverse reactions associated with psychotropic medications. Polypharmacy and the similar presentation of SS and NMS make diagnosis of the 2 syndromes problematic.
Methods
A MEDLINE search was performed for the period 1960 to 2011 for case reports, review articles, and studies pertaining to SS and NMS.
Results
The majority of available literature on SS and NMS consists of case reports, case-control studies, and retrospective reviews. In addition, diagnostic criteria have been developed to aid in the diagnosis and management of SS and NMS.
Conclusions
SS presents as mental status changes, autonomic nervous system disturbances, neurologic manifestations, and hyperthermia. Similarly, NMS presents as muscle rigidity, hyperpyrexia, mental status changes, and autonomic instability. However, the clinical laboratory profile of elevations in creatine kinase, liver function tests (lactate dehydrogenase, aspartate transaminase), and white blood cell count, coupled with a low serum iron level, distinguishes NMS from SS among patients taking neuroleptic and serotonin agonist medications simultaneously. For both SS and NMS, immediate discontinuation of the causative agent is the primary treatment, along with supportive care. For NMS, dantrolene is the most effective evidence-based drug treatment whereas there are no evidence-based drug treatments for SS. A 2-week washout of neuroleptic medication minimizes the chance of recurrence.
CirauloDA, ShaderRI.Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics. J Clin Psychopharmacol. 1990;10:48–50.
2.
SternbachH.The serotonin syndrome. Am J Psychiatry. 1991;148:705–713.
3.
DelayJ, PichotP, LemperiereT, . A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses. Ann Med Psychol (Paris). 1960;118:145–152.
4.
DelayJ, DenikerP.Drug induced extrapyramidal syndromes. In: VinkinPJ, BruynGW, eds. Handbook of clinical neurology: diseases of the basal ganglia. Vol 6. New York, NY: American Elsevier/North Holland Publishing; 1968:248–266.
5.
GelenbergAJ, BellinghausenB, WojcikJD, . A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry. 1988;145:517–518.
6.
KeckPEJr, SebastianelliJ, PopeHGJr, . Frequency and presentation of neuroleptic malignant syndrome in a state psychiatric hospital. J Clin Psychiatry. 1989;50:352–355.
7.
HermeshH, AizenbergD, WeizmanA, . Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients. Br J Psychiatry. 1992;161:254–257.
8.
KeckPEJr, PopeHGJr, McElroySL.Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry. 1991;148:880–882.
9.
ParrottAC.Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav. 2002;71:837–844.
10.
LawrenceKR, AdraM, GillmanPK.Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis. 2006;42:1578–1583.
11.
OatesJA, SjoerdsmaA.Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology. 1960;10:1076–1078.
12.
MillerDD, SharafuddinMJ, KatholRG.A case of clozapine-induced neuroleptic malignant syndrome. J Clin Psychiatry. 1991;52:99–101.
13.
ReddigS, MinnemaAM, TandonR.Neuroleptic malignant syndrome and clozapine. Ann Clin Psychiatry. 1993;5:25–27.
14.
SachdevP, KrukJ, KneeboneM, . Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol. 1995;15:365–371.
15.
ThornbergSA, EreshefskyL.Neuroleptic malignant syndrome associated with clozapine monotherapy. Pharmacotherapy. 1993;13:510–514.
16.
FriedmanJH, FeinbergSS, FeldmanRG.A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. JAMA. 1985;254:2792–2795.
17.
SimpsonDM, DavisGC.Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine. Am J Psychiatry. 1984;141:796–797.
GurreraRJ.Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry. 1999;156:169–180.
20.
KeckPEJr, PopeHGJr, CohenBM, . Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry. 1989;46:914–918.
21.
CaroffSN, MannSC, CampbellEC.Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatr Ann. 2000;30:314–321.
22.
ViejoLF, MoralesV, PuñalP, . Risk factors in neuroleptic malignant syndrome. A case-control study. Acta Psychiatr Scand. 2003;107:45–49.
23.
AddonizioG, SusmanVL, RothSD.Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry. 1987;22:1004–1020.
24.
CaroffSN, MannSC.Neuroleptic malignant syndrome. Med Clin North Am. 1993;77:185–202.
25.
RosebushP, StewartT.A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989;146:717–725.
26.
DengMZ, ChenGQ, PhillipsMR.Neuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics: a prospective study. Am J Psychiatry. 1990;147:1149–1155.
27.
DavisJM, JanicakPG, SakkasP, . Electroconvulsive therapy in the treatment of the neuroleptic malignant syndrome. Convuls Ther. 1991;7:111–120.
28.
Krivosic-HorberR, AdnetP, GuevartE, . Neuroleptic malignant syndrome and malignant hyperthermia. In vitro comparison with halothane and caffeine contracture tests. Br J Anaesth. 1987;59:1554–1556.
29.
AdnetPJ, Krivosic-HorberRM, AdamantidisMM, . The association between the neuroleptic malignant syndrome and malignant hyperthermia. Acta Anaesthesiol Scand. 1989;33:676–680.
30.
ParkeTJ, WheatleySA.Anaesthesia in the neuroleptic malignant syndrome. Anaesthesia. 1992;47:908–909.
LatzSR, McCrackenJT.Neuroleptic malignant syndrome in children and adolescents: two case reports and a warning. J Child Adolesc Psychopharmacol. 1992;2:123–129.
33.
PetersonSE, MeyersKM, McClellanJ, . Neuroleptic malignant syndrome: three adolescents with complicated courses. J Child and Adolesc Psychopharmacol. 1995;5:139–149.
34.
SteingardR, KhanA, GonzalezA, . Neuroleptic malignant syndrome: review of experience with children and adolescents. J Child Adolesc Psychopharmacol. 1992;2:183–198.
35.
ShalevA, HermeshH, MunitzH.The role of external heat load in triggering the neuroleptic malignant syndrome. Am J Psychiatry. 1988;145:110–111.
36.
GurreraRJ, RomeroJA.Enzyme elevations in the neuroleptic malignant syndrome. Biol Psychiatry. 1993;34:634–640.
37.
KeckPEJr, ArnoldLM.Serotonin syndrome. Psychiatr Ann. 2000;30:333–343.
38.
Heiman-PattersonTD.Neuroleptic malignant syndrome and malignant hyperthermia. Important issues for the medical consultant. Med Clin North Am. 1993;77:477–492.
39.
EiserAR, NeffMS, SlifkinRF.Acute myoglobinuric renal failure. A consequence of the neuroleptic malignant syndrome. Arch Intern Med. 1982;142:601–603.
40.
RosebushPI, MazurekMF.Serum iron and neuroleptic malignant syndrome. Lancet. 1991;338:149–151.
41.
RajaM, AltavistaMC, CavallariS, . Neuroleptic malignant syndrome and catatonia. A report of three cases. Eur Arch Psychiatry Clin Neurosci. 1994;243:299–303.
ChenCC, ReistC, KoWK.A follow-up of patients with neuroleptic malignant syndrome. Hosp Community Psychiatry. 1991;42:197–199.
44.
RadomskiJW, DursunSM, ReveleyMA, . An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses. 2000;55:218–224.
45.
DunkleyEJ, IsbisterGK, SibbrittD, . The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96:635–642.
46.
GurreraRJ, ChangSS, RomeroJA.A comparison of diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychiatry. 1992;53:56–62.
47.
Diagnostic and statistical manual of mental disorders, 4th ed, text rev. Washington, DC:American Psychiatric Association; 2000.
48.
LappinRI, AuchinclossEL.Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med. 1994;331:1021–1022.
49.
GoldwasserHD, HooperJF, SpearsNM.Concomitant treatment of neuroleptic malignant syndrome and psychosis. Br J Psychiatry. 1989;154:102–104.
50.
DiedlerJ, MelladoP, VeltkampR.Endovascular cooling in a patient with neuroleptic malignant syndrome. J Neurol Sci. 2008;264:163–165.
51.
SakkasP, DavisJM, HuaJ, . Pharmacotherapy of neuroleptic malignant syndrome. Psychiatr Ann. 1991;21:157–164.
52.
MannSC, CaroffSN, BleierHR, . Electroconvulsive therapy of the lethal catatonia syndrome. Convuls Ther. 1990;6:239–247.
53.
TrollorJN, SachdevPS.Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry. 1999;33:650–659.
54.
SusmanVL, AddonizioG.Recurrence of neuroleptic malignant syndrome. J Nerv Ment Dis. 1988;176:234–241.
55.
RosebushPI, StewartTD, GelenbergAJ.Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry. 1989;50:295–298.
56.
WellsAJ, SommiRW, CrismonML.Neuroleptic rechallenge after neuroleptic malignant syndrome: case report and literature review. Drug Intell Clin Pharm. 1988;22:475–480.
57.
Gomez-EstebanJC, BarcenaJ, ForcadasM, . Neuroleptic malignant syndrome and serotonin syndrome in a female patient: a clinicopathologic case. Clin Neuropharmacol. 2009;32:299–300.
